REVELATION BIOSCIENCES INC

For the period ended Sep 30, 2024. Filed Nov 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 8, 2024

REVB$3.94-4.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

Series A Preferred Stock · Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
	Shares	Amount	Shares	Amount	Capital	Deficit	Equity
Balance at December 31, 2022	1	$—	77,375	$77	$26,399,224	$(25,346,848)	$1,052,453
Redemption of Series A Preferred Stock	(1)	—	—	—	—	—	—
Issuance of common stock from the February 2023 Public Offering	—	—	96,287	96	33,378	—	33,474
Class C Pre-Funded Warrants exercise	—	—	6,434	7	12	—	19
Alternative cashless exercise of Class C Common Stock Warrants	—	—	32,190	32	2,740,378	—	2,740,410
Stock-based compensation expense	—	—	—	—	32,095	—	32,095
Net income	—	—	—	—	—	6,159,195	6,159,195
Balance as of March 31, 2023	—	$—	212,286	$212	$29,205,087	$(19,187,653)	$10,017,646
Class C Pre-Funded Warrants exercise	—	—	4,780	5	10	—	15
Alternative cashless exercise of Class C Common Stock Warrants	—	—	47,331	47	2,785,830	—	2,785,877
RSU awards issued	—	—	140	1	(1)	—	—
Stock-based compensation expense	—	—	—	—	59,435	—	59,435
Net loss	—	—	—	—	—	(1,448,170)	(1,448,170)
Balance as of June 30, 2023	—	$—	264,537	$265	$32,050,361	$(20,635,823)	$11,414,803
Stock-based compensation expense	—	—	—	—	32,096	—	32,096
Net loss	—	—	—	—	—	(2,628,376)	(2,628,376)
Balance as of September 30, 2023	—	$—	264,537	$265	$32,082,457	$(23,264,199)	$8,818,523
Balance at December 31, 2023	—	$—	264,537	$265	$32,114,552	$(25,467,102)	$6,647,715
Issuance of common stock from the February 2024 Public Offering	—	—	128,470	128	5,416,925	—	5,417,053
Class D Pre-Funded Warrants exercise	—	—	1,236,530	1,237	(1,110)	—	127
Alternative cashless exercise of Class C Common Stock Warrants	—	—	3,398	3	57,586	—	57,589
Stock-based compensation expense	—	—	—	—	32,094	—	32,094
Net loss	—	—	—	—	—	(2,681,433)	(2,681,433)
Balance as of March 31, 2024	—	$—	1,632,935	$1,633	$37,620,047	$(28,148,535)	$9,473,145
Common stock issued for services	—	—	10,460	10	24,990	—	25,000
Stock-based compensation expense	—	—	—	—	32,095	—	32,095
Net loss	—	—	—	—	—	(8,389,819)	(8,389,819)
Balance as of June 30, 2024	—	$—	1,643,395	$1,643	$37,677,132	$(36,538,354)	$1,140,421
Class D Common Stock Warrants exercises	—	—	101,000	101	241,289	—	241,390
Warrant Inducement exercises	—	—	2,548,060	2,548	3,498,728	—	3,501,276
Stock-based compensation expense	—	—	—	—	32,095	—	32,095
Net loss	—	—	—	—	—	(2,241,565)	(2,241,565)
Balance as of September 30, 2024	—	$—	4,292,455	$4,292	$41,449,244	$(38,779,919)	$2,673,617

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.